Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (unaudited) - USD ($) $ in Thousands	Total	Previously Reported	Revision of Prior Period, Adjustment	Common Stock	Common Stock Previously Reported	Common Stock Revision of Prior Period, Adjustment	Additional Paid-in Capital	Additional Paid-in Capital Previously Reported	Additional Paid-in Capital Revision of Prior Period, Adjustment	Treasury Stock	Treasury Stock Previously Reported	Treasury Stock Revision of Prior Period, Adjustment	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Previously Reported	Accumulated Other Comprehensive Income (Loss) Revision of Prior Period, Adjustment	Accumulated Deficit	Accumulated Deficit Previously Reported	Accumulated Deficit Revision of Prior Period, Adjustment
Beginning balance (in shares) at Dec. 31, 2024	0	212,541,832	(212,541,832)
Beginning balance at Dec. 31, 2024	$ 0	$ 1,363,580	$ (1,363,580)
Ending balance (in shares) at Mar. 31, 2025	0
Ending balance at Mar. 31, 2025	$ 0
Beginning balance (in shares) at Dec. 31, 2024				67,861,240	25,973,713	41,887,527
Beginning balance at Dec. 31, 2024	308,563	$ (1,055,017)	$ 1,363,580	$ 7	$ 3	$ 4	$ 1,438,835	$ 75,259	$ 1,363,576	$ (2,619)	$ (2,619)	$ 0	$ 102	$ 102	$ 0	$ (1,127,762)	$ (1,127,762)	$ 0
Increase (Decrease) in Stockholders' Equity
Retirement of treasury stock	0						(2,619)			2,619
Issuance of shares upon exercise of stock options (in shares)				2,424
Issuance of shares upon exercise of stock options	22						22
Stock-based compensation expense	2,276						2,276
Unrealized gain (loss) on available-for-sale securities	(82)												(82)
Foreign currency translation adjustments	15												15
Net income (loss)	(57,874)															(57,874)
Ending balance (in shares) at Mar. 31, 2025				67,863,664
Ending balance at Mar. 31, 2025	$ 252,920			$ 7			1,438,514			0			35			(1,185,636)
Beginning balance (in shares) at Dec. 31, 2024	0	212,541,832	(212,541,832)
Beginning balance at Dec. 31, 2024	$ 0	$ 1,363,580	$ (1,363,580)
Ending balance (in shares) at Sep. 30, 2025	0
Ending balance at Sep. 30, 2025	$ 0
Beginning balance (in shares) at Dec. 31, 2024				67,861,240	25,973,713	41,887,527
Beginning balance at Dec. 31, 2024	308,563	$ (1,055,017)	$ 1,363,580	$ 7	$ 3	$ 4	1,438,835	75,259	1,363,576	(2,619)	$ (2,619)	$ 0	102	102	0	(1,127,762)	(1,127,762)	0
Increase (Decrease) in Stockholders' Equity
Unrealized gain (loss) on available-for-sale securities	(69)
Foreign currency translation adjustments	35
Net income (loss)	(181,074)
Ending balance (in shares) at Sep. 30, 2025				67,907,597
Ending balance at Sep. 30, 2025	$ 135,690			$ 7			1,444,451			0			68			(1,308,836)
Beginning balance (in shares) at Mar. 31, 2025	0
Beginning balance at Mar. 31, 2025	$ 0
Ending balance (in shares) at Jun. 30, 2025	0
Ending balance at Jun. 30, 2025	$ 0
Beginning balance (in shares) at Mar. 31, 2025				67,863,664
Beginning balance at Mar. 31, 2025	252,920			$ 7			1,438,514			0			35			(1,185,636)
Increase (Decrease) in Stockholders' Equity
Issuance of shares upon exercise of stock options (in shares)				16,770
Issuance of shares upon exercise of stock options	82						82
Stock-based compensation expense	2,738						2,738
Unrealized gain (loss) on available-for-sale securities	(5)												(5)
Foreign currency translation adjustments	49												49
Net income (loss)	(58,731)															(58,731)
Ending balance (in shares) at Jun. 30, 2025				67,880,434
Ending balance at Jun. 30, 2025	$ 197,053			$ 7			1,441,334			0			79			(1,244,367)
Ending balance (in shares) at Sep. 30, 2025	0
Ending balance at Sep. 30, 2025	$ 0
Increase (Decrease) in Stockholders' Equity
Issuance of shares upon exercise of stock options (in shares)				27,163
Issuance of shares upon exercise of stock options	286						286
Stock-based compensation expense	2,831						2,831
Unrealized gain (loss) on available-for-sale securities	18												18
Foreign currency translation adjustments	(29)												(29)
Net income (loss)	(64,469)															(64,469)
Ending balance (in shares) at Sep. 30, 2025				67,907,597
Ending balance at Sep. 30, 2025	$ 135,690			$ 7			1,444,451			$ 0			68			(1,308,836)
Beginning balance (in shares) at Dec. 31, 2025	0	212,541,832	(212,541,832)
Beginning balance at Dec. 31, 2025	$ 0	$ 1,363,580	$ (1,363,580)
Ending balance (in shares) at Mar. 31, 2026	0
Ending balance at Mar. 31, 2026	$ 0
Beginning balance (in shares) at Dec. 31, 2025	67,944,192			67,944,192	26,267,598	41,676,594
Beginning balance at Dec. 31, 2025	$ 100,444	$ (1,263,136)	$ 1,363,580	$ 7	$ 3	$ 4	1,447,410	83,834	1,363,576				132	132	0	(1,347,105)	(1,347,105)	0
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	2,903						2,903
Unrealized gain (loss) on available-for-sale securities	(87)												(87)
Foreign currency translation adjustments	(19)												(19)
Net income (loss)	(63,559)															(63,559)
Ending balance (in shares) at Mar. 31, 2026				67,944,192
Ending balance at Mar. 31, 2026	$ 39,682			$ 7			1,450,313						26			(1,410,664)
Beginning balance (in shares) at Dec. 31, 2025	0	212,541,832	(212,541,832)
Beginning balance at Dec. 31, 2025	$ 0	$ 1,363,580	$ (1,363,580)
Ending balance (in shares) at Sep. 30, 2026	0
Ending balance at Sep. 30, 2026	$ 0
Beginning balance (in shares) at Dec. 31, 2025	67,944,192			67,944,192	26,267,598	41,676,594
Beginning balance at Dec. 31, 2025	$ 100,444	$ (1,263,136)	$ 1,363,580	$ 7	$ 3	$ 4	1,447,410	$ 83,834	$ 1,363,576				132	$ 132	$ 0	(1,347,105)	$ (1,347,105)	$ 0
Increase (Decrease) in Stockholders' Equity
Unrealized gain (loss) on available-for-sale securities	(475)
Foreign currency translation adjustments	(19)
Net income (loss)	$ (72,478)
Ending balance (in shares) at Sep. 30, 2026	110,870,300			110,870,300
Ending balance at Sep. 30, 2026	$ 481,329			$ 11			1,901,263						(362)			(1,419,583)
Beginning balance (in shares) at Mar. 31, 2026	0
Beginning balance at Mar. 31, 2026	$ 0
Ending balance (in shares) at Jun. 30, 2026	0
Ending balance at Jun. 30, 2026	$ 0
Beginning balance (in shares) at Mar. 31, 2026				67,944,192
Beginning balance at Mar. 31, 2026	39,682			$ 7			1,450,313						26			(1,410,664)
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	2,734						2,734
Unrealized gain (loss) on available-for-sale securities	2												2
Net income (loss)	(69,029)															(69,029)
Ending balance (in shares) at Jun. 30, 2026				67,944,192
Ending balance at Jun. 30, 2026	$ (26,611)			$ 7			1,453,047						28			(1,479,693)
Ending balance (in shares) at Sep. 30, 2026	0
Ending balance at Sep. 30, 2026	$ 0
Increase (Decrease) in Stockholders' Equity
Exercise of penny warrants (in shares)				121,237
Vesting of restricted stock units, net of shares withheld for taxes (in shares)	58,672			58,672
Vesting of restricted stock units, net of shares withheld for taxes	$ (1,096)						(1,096)
Stock-based compensation expense	41,944						41,944
Unrealized gain (loss) on available-for-sale securities	(390)												(390)
Foreign currency translation adjustments	0
Issuance of common stock upon Business Combination to PCSC public shareholders and Sponsor, net of transaction costs (in shares)				8,920,769
Issuance of common stock upon Business Combination to PCSC public shareholders and Sponsor, net of transaction costs	64,864			$ 1			64,863
Issuance of common stock upon PIPE Financing, net of transaction costs (in shares)				24,000,000
Issuance of common stock upon PIPE Financing, net of transaction costs	220,112			$ 2			220,110
Issuance of common stock upon conversion of convertible notes (in shares)				9,825,430
Issuance of common stock upon conversion of convertible notes	122,396			$ 1			122,395
Net income (loss)	$ 60,110															60,110
Ending balance (in shares) at Sep. 30, 2026	110,870,300			110,870,300
Ending balance at Sep. 30, 2026	$ 481,329			$ 11			$ 1,901,263						$ (362)			$ (1,419,583)
Beginning balance (in shares) at Jul. 19, 2026	212,541,832
Beginning balance at Jul. 19, 2026	$ 1,400,000
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon PIPE Financing, net of transaction costs (in shares)	32,920,769
Ending balance (in shares) at Jul. 20, 2026	107,446,814